Animal Vaccine Market to Reach $23,604.7 Million by 2035
Animal vaccine market is driven by the rising prevalence of zoonotic and infectious animal diseases, increasing demand for livestock health management, and growing awareness regarding animal welfare and food safety. Expanding livestock production, rising pet adoption rates, and increasing investments in veterinary healthcare infrastructure are further supporting market growth globally. In addition, advancements in vaccine technologies such as recombinant, DNA, vectored, and subunit vaccines are improving disease prevention efficiency, enhancing immunity, and encouraging widespread adoption across companion animals, poultry, aquaculture, and livestock sectors.
Browse the full report description of “Animal Vaccine Market Size, Share & Trends Analysis Report by Type (Porcine Vaccines, Poultry Vaccines, Livestock Vaccines, Aquaculture Vaccines, Companion Animal Vaccines, and Other Animal Vaccines) By Technology (Live Attenuated Vaccine, Killed/Inactive Vaccine, Recombinant Vaccine, Vectored Vaccine, Subunit Vaccine, DNA Vaccine, Chimeric Vaccine, and Others) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/animal-vaccine-market/
Avian influenza poultry vaccines segment is expected to account for a major market share in 2025
Avian influenza poultry vaccines are expected to hold a major market share in 2025, primarily due to the increasing prevalence of H5N1 outbreaks across commercial poultry flocks and rising focus on disease prevention within the global poultry industry. These vaccines are increasingly utilized to reduce infection spread, protect poultry health, and strengthen biosecurity measures across large-scale poultry farming operations. Zoetis received conditional USDA approval in 2025 for its Avian Influenza Vaccine, H5N2 Subtype, highlighting the growing emphasis on poultry protection initiatives amid expanding avian influenza concerns. Increasing investments in livestock disease prevention and rising adoption of preventive veterinary healthcare solutions are expected to significantly support segment growth.
Long-duration companion animal preventive care segment is expected to account for a major market share in 2025
Long-duration companion animal preventive care solutions are expected to hold a major market share in 2025 owing to the increasing demand for convenient and extended-duration veterinary healthcare products for pets. These solutions improve treatment compliance, reduce frequent dosing requirements, and support long-term flea, tick, and parasite protection for companion animals. Merck Animal Health expanded its companion animal vaccine and preventive portfolio during 2025 through FDA approval of BRAVECTO® QUANTUM, a once-yearly injectable flea and tick protection product for dogs. Growing pet ownership, increasing spending on companion animal healthcare, and rising demand for long-acting veterinary therapeutics are expected to further accelerate the growth of the long-duration companion animal preventive care segment.
Canine influenza vaccines segment is expected to account for a major market share in 2025
Canine influenza vaccines are expected to hold a major market share in 2025 due to the increasing prevalence of respiratory diseases in companion animals and growing awareness regarding preventive veterinary vaccination programs. These vaccines are widely utilized to protect dogs against highly contagious canine influenza virus (CIV) strains and improve overall respiratory disease management in veterinary healthcare settings. Elanco Animal Health received USDA approval in 2025 for TruCan™ Ultra CIV H3N2/H3N8, a canine influenza vaccine developed to provide broad respiratory disease protection against both major CIV strains in the United States market. Rising adoption of preventive pet healthcare services and increasing veterinary vaccination rates are expected to significantly contribute to segment growth.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404